Clinical Trials Logo

KRAS Gene Mutation clinical trials

View clinical trials related to KRAS Gene Mutation.

Filter by:

NCT ID: NCT04965818 Terminated - Clinical trials for Non-Small Cell Lung Cancer

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Start date: September 20, 2021
Phase: Phase 1
Study type: Interventional

Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.

NCT ID: NCT04446793 No longer available - Clinical trials for Metastatic Colorectal Cancer

Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program for eligible participants designed to provide access to onvansertib in combination with FOLFIRI and bevacizumab.

NCT ID: NCT03965845 Completed - Solid Tumors Clinical Trials

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Start date: June 25, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with advanced/metastatic solid tumors.

NCT ID: NCT03829410 Completed - Clinical trials for Metastatic Colorectal Cancer

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

Start date: May 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line treatment in adult participants who have metastatic colorectal cancer with a Kras mutation. Participants must have histologically confirmed metastatic and unresectable disease, and previously failed treatment or be intolerant to fluoropyrimidine and oxaliplatin with or without bevacizumab.

NCT ID: NCT03808558 Recruiting - KRAS Gene Mutation Clinical Trials

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Start date: September 11, 2019
Phase: Phase 2
Study type: Interventional

This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.

NCT ID: NCT03777124 Not yet recruiting - Chemotherapy Effect Clinical Trials

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Start date: February 2019
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small Cell Lung Cancer

NCT ID: NCT03750175 Completed - Clinical trials for Colorectal Cancer Metastatic

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

OPTIPAL-II
Start date: June 1, 2018
Phase:
Study type: Observational

The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.

NCT ID: NCT03704688 Completed - Clinical trials for Non Small Cell Lung Cancer

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Start date: October 9, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.

NCT ID: NCT03520842 Completed - Clinical trials for Metastatic Malignant Neoplasm in the Brain

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Start date: August 14, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well regorafenib works together with methotrexate in treating participants with metastatic non-squamous non-small cell lung cancer with tumors that harbor a KRAS mutation. Regorafenib is a targeted therapy that works on different cancer pathways to stop the growth of tumor cells and stop them from spreading. Methotrexate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving regorafenib and methotrexate together may work in treating participants with KRAS mutated non-small cell lung cancer.

NCT ID: NCT03299088 Active, not recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer AJCC v7

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

Start date: June 26, 2018
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects of pembrolizumab and trametinib in treating patients with non-small cell lung cancer and KRAS gene mutations that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and trametinib may work better in treating patients with non-small cell lung cancer.